Plain-English translation of NCT06929169 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether SGLT2 inhibitors—a class of medication originally developed for diabetes—can help protect the hearts of people with end-stage kidney disease who depend on dialysis. People on dialysis face a very high risk of heart problems and heart failure, even when their hearts pump normally. Researchers believe this medication might reduce inflammation and scarring in the heart muscle, which could lower that risk.
Heart disease is the leading cause of death in dialysis patients, often appearing as stiffness and scarring in the heart that current treatments don't fully address. Early research suggests this medication may have special protective effects on the heart that could benefit this vulnerable group.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to either receive the new medication once daily by mouth (in addition to your regular dialysis care) or to continue with standard dialysis care alone. Either way, you'll visit the clinic for detailed heart monitoring at the start, and again at 3, 6, and 12 months. These visits will include heart scans (cardiac MRI and ultrasound), electrical heart monitoring, blood tests, and other measurements—allowing researchers to see whether the medication is protecting your heart.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
Argentina